Opioid Use Disorder
Research Study
Researchers at Maryland Treatment Centers are partnering with adults who have opioid use disorder to investigate a new method of opioid detox relapse prevention medication. Join our compensated study today!
Fast Facts
18+ Years Old
Use opioids regularly or have opioid use disorder
Compensation up to $560 Provided
conducted in Baltimore and rockville, mD
Study Background
Researchers at Maryland Treatment Centers (MTC) are conducting a research study to test a new combination of medicines for outpatient treatment of opioid withdrawal.
Findings from this clinical research study will determine whether new approaches to treating withdrawal will improve our ability to use extended-release naltrexone (Vivitrol) as a relapse prevention medication.
This study involves a prescreening over the phone, and in-person screening visits. Participants will be randomized to receive either Lofexidine+Pregabalin OR Lofexidine+Placebo. There will be daily check-ins during the 8-day outpatient opioid detoxification to determine withdrawal symptoms.
Further research today and join our compensated study!
Study Background
Researchers at Maryland Treatment Centers (MTC) are conducting a research study to test a new combination of medicines for outpatient treatment of opioid withdrawal.
Findings from this clinical research study will determine whether new approaches to treating withdrawal will improve our ability to use extended-release naltrexone (Vivitrol) as a relapse prevention medication.
This study involves a prescreening over the phone, and in-person screening visits. Participants will be randomized to receive either Lofexidine+Pregabalin OR Lofexidine+Placebo. There will be daily check-ins during the 8-day outpatient opioid detoxification to determine withdrawal symptoms.
Further research today and join our compensated study!
Additional Information
You may qualify for this study if you meet the following criteria:
Key Criteria:
- 18+ years old
- Use opioids regularly or have opioid use disorder
- Able to come to the clinic in Baltimore or Rockville, MD for study visits
- Potentially interested in extended-release naltrexone (Vivitrol) as a relapse prevention medication
- Not currently pregnant or breastfeeding
- Not currently receiving opioids for pain management
- Not in a methadone or buprenorphine treatment program within last 30 days
Once enrolled, this study involves:
- Completing a prescreening over the phone
- Attending an in-person screening visit
- Participating in an 8 day outpatient detoxification period
- Day 1: Randomization (in person)
- Day 2: In person study visit
- Day 3: Remote study visit
- Day 4: In person study visit
- Day 5: Remote study visit
- Day 6: Remote study visit
- Day 7: In person study visit
- Day 8: In person study visit + Vivitrol (optional)
- Day 11: In person study visit
- Day 28: In person study visit
